Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6502545 | 0.95 | TSHR (0.53) | SMN1; SMN2NPC1RAB9ATSHRMAPT | |
| SCHEMBL6500660 | 0.95 | TSHR (0.53) | SMN1; SMN2NPC1RAB9ATSHRMAPT | |
| SCHEMBL6506436 | 0.95 | TSHR (0.53) | SMN1; SMN2NPC1RAB9ATSHRMAPT | |
| SCHEMBL6427188 | 0.85 | ALDH1A1 (0.57) | SMN1; SMN2TSHRLMNACYP3A4MAPT | |
| SCHEMBL6426510 | 0.85 | ALDH1A1 (0.57) | SMN1; SMN2TSHRLMNACYP3A4MAPT | |
| SCHEMBL6393517 | 0.84 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9ALMNACYP3A4 | |
| SCHEMBL6507694 | 0.83 | ALDH1A1 (0.46) | SMN1; SMN2LMNAMAPTALDH1A1KMT2A | |
| SCHEMBL1605788 | 0.82 | TSHR (0.46) | SMN1; SMN2NPC1RAB9ATSHRLMNA | |
| SCHEMBL6507627 | 0.82 | GRM7 (0.46) | SMN1; SMN2NPC1RAB9ATSHRMAPT | |
| SCHEMBL6428159 | 0.82 | GRM7 (0.46) | SMN1; SMN2NPC1RAB9ATSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | claimed |
| US-20050239853-A1 | New compounds | BIOVITRUM AB (SE) | 2005-10-27 | — | — | US | disclosed |
| WO-2005075471-A2 | THIAZOL-COMPOUNDS AS 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS | BIOVITRUM AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239853-A1 | New compounds | HSD11B1, CYP11B1, HSD3B1 | SMN1; SMN2 3733/4885NPC1 277/4885RAB9A 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.